---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-387890"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2026-09-10T20:13:52+00:00"
generated_at: "2026-09-10T20:15:15.877798+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lyell completes LYL273 manufacturing transfer to LyFE; Phase 1/2 data and FDA meeting expected 2027

## Summary
- Completed technology transfer of LYL273 to LyFE Manufacturing Center in Bothell, WA after FDA review of improved process and analytical methods.
- Phase 1/2 trial in relapsed/refractory metastatic colorectal cancer continues enrolling; goal to determine recommended Phase 2 dose and safety plan.
- Additional clinical data and End-of-Phase 1 meeting with FDA now expected in 2027.
- CEO Lynn Seely notes encouraging clinical activity data and activation of additional clinical sites for expansion phase.

## SEC filing metadata
- accession: 0001193125-26-387890
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2026-09-10T20:13:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312526387890/0001193125-26-387890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312526387890/d278670d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-387890
- JSON: https://secwatch.observer/filing/0001193125-26-387890.json
- Plain text: https://secwatch.observer/filing/0001193125-26-387890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.